What happened with BLRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
BioLineRX Ltd develops medicines for cancer and rare diseases, often taking licensed compounds through further development. Its first approved drug, APHEXDA (motixafortide), helps move blood-forming stem cells from bone marrow into the bloodstream for collection. In the United States, it is approved for patients with multiple myeloma preparing for a transplant using their own stem cells.
The company no longer sells APHEXDA directly in the United States. Its current revenue comes principally from royalties paid by Ayrmid on U.S. APHEXDA sales. Ayrmid holds commercialization rights outside Asia, excluding solid-tumor uses; Gloria holds development and commercialization rights across substantially all of Asia. These agreements also provide for payments when specified development, regulatory or sales targets are met. Revenue therefore depends heavily on these partners selling the drug and reaching those targets.
BioLineRX retains motixafortide rights for solid tumors outside Asia and is developing it for pancreatic cancer. It also works with Hemispherian through Tetragon to develop GLIX1, initially for glioblastoma. These uses remain in development and require regulatory approval. The company needs additional funding for research and development. Further licensing of motixafortide, and transfers of its technology or manufacturing outside Israel, are subject to Israel Innovation Authority consent requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BioLineRx’s near-term revenue depends chiefly on Ayrmid’s APHEXDA sales and Gloria’s Asian license milestones and sales, while Hemispherian partners with it on GLIX1 development.
Sanofi’s Mozobil competes directly with BioLineRx’s APHEXDA to help patients mobilize stem cells before receiving a transplant using their own cells. Watch Mozobil alongside the generic plerixafor products launched at substantially lower prices after its last U.S.-listed patent expired in the third quarter of 2023.
Exicure’s investigational burixafor could become a competitor in the multiple-myeloma stem-cell-mobilization use that generates BioLineRx’s APHEXDA royalties from Ayrmid. Watch its clinical development with propranolol and G-CSF, rather than treating it as an already marketed rival.
Dr. Reddy’s Laboratories sells generic plerixafor that competes with APHEXDA in stem-cell mobilization, the market behind BioLineRx’s royalties from Ayrmid. Its plerixafor pricing and sales are the relevant business to watch: these generics launched at substantially lower prices than Mozobil.
Amneal Pharmaceuticals’ generic plerixafor competes for the stem-cell-mobilization patients served by APHEXDA, whose sales generate royalties for BioLineRx. Amneal sells generic medicines and injectables; its plerixafor offering matters here because it launched at substantially lower prices than branded Mozobil.
Teva’s generic plerixafor competes with APHEXDA in stem-cell mobilization and pressures BioLineRx’s opportunity to earn royalties from Ayrmid’s sales. Watch that product’s pricing and uptake, not Teva’s broad medicine portfolio: the generic launched at substantially lower prices than Mozobil.
Regeneron and BioLineRx equally support a trial combining Regeneron’s cemiplimab with BioLineRx’s motixafortide and chemotherapy as first-line pancreatic-cancer treatment. The planned 2026 interim analysis of whether the trial should stop for lack of benefit is the concrete checkpoint for BioLineRx’s combination.
Revolution Medicines’ late-stage daraxonrasib competes with BioLineRx’s motixafortide combination in pancreatic-cancer development. Watch daraxonrasib’s results in metastatic pancreatic cancer; Revolution is developing targeted cancer medicines, not reporting an approved-product business here.
Arcus Biosciences’ quemliclustat is being developed for pancreatic cancer alongside BioLineRx’s motixafortide combination, giving investors another program to watch in the same disease. Its late-stage metastatic pancreatic-cancer results are more relevant to this tie than sales, since Arcus’s business centers on clinical development rather than approved medicines.
Cerenome’s investigational rhenium obisbemeda competes for recurrent-glioblastoma patients in the market BioLineRx is targeting with GLIX1. Watch that treatment’s development rather than Cerenome’s separate diagnostic-test business, which detects cancer cells that have spread to the central nervous system.
NovoCure’s marketed Optune Gio indirectly competes with BioLineRx’s developing GLIX1 in glioblastoma, while Optune Pax treats locally advanced pancreatic cancer. NovoCure sells devices that deliver electric fields to disrupt cancer-cell division; Optune Gio’s active-patient numbers and revenue per active patient show the scale of this established treatment.
Dr. Reddy's Laboratories Limited earningsRDY
Dr. Reddy’s report can show how its generic plerixafor sales and pricing are shaping the low-priced competition facing BioLineRx’s APHEXDA.
If the report provides the detail, read generic plerixafor sales alongside its pricing. Stronger sales or persistently low prices would point to tougher competition in the stem-cell-mobilization market for APHEXDA and could constrain BioLineRx’s royalties through Ayrmid; weak generic sales or easing price pressure would mean less pressure from this competitor, not proof that APHEXDA sales are growing. The question is whether low-priced generics are intensifying the market squeeze.
Regeneron Pharmaceuticals Inc earningsREGN
Regeneron’s report may update the shared pancreatic-cancer trial and show whether the development path for BioLineRx’s motixafortide combination is continuing.
Look for an update on the trial’s interim analysis and whether it was stopped for lack of benefit. If it continues past that stopping checkpoint, BioLineRx’s motixafortide combination remains in development, but its benefit is not established; if the trial stops for lack of benefit, that is a setback for the program in this setting. The takeaway is whether the combination still has a chance to be tested further.
Revolution Medicines, Inc. earningsRVMD
Revolution Medicines’ report can show how its investigational pancreatic-cancer drug daraxonrasib is progressing against BioLineRx’s development program in the same disease.
Look for updates on daraxonrasib’s development and results in metastatic pancreatic cancer, keeping its program distinct from BioLineRx’s motixafortide combination. Supported progress would show a competing program advancing in the same disease area and raise the evidence bar for BioLineRx; limited or delayed progress would mean less pressure from this candidate, not proof that motixafortide works. The takeaway is whether this rival program is raising the competitive bar.
BioLineRX Ltd earningsThis company
BioLineRx relies chiefly on royalties tied to APHEXDA while funding drug development, so this report shows whether royalty income is keeping its cash use manageable.
Read APHEXDA-related royalties alongside cash used in operations and the cash balance. Rising royalties with contained cash use would suggest existing funds can support development for longer; weak royalties while cash keeps flowing out would mean greater reliance on financing or further cuts. One report cannot guarantee how long cash will last, so the key is whether income and spending are moving in a sustainable direction.
